Publications
Explore peer-reviewed scientific publications related to Alnylam’s licensed medicines in the UK (vutrisiran▼, patisiran, givosiran▼ and lumasiran) and their therapeutic areas.
Information on investigational products or unlicensed indications is not included on this website.
The materials in this section are intended for UK healthcare professionals and include scientific and educational publications. The information contained in these publications was accurate at the time of publication. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].
UK healthcare professionals seeking details which cannot not be found below, may contact Alnylam Medical, where enquiries will be handled in accordance with UK Medical Information requirements.
Transthyretin Amyloidosis (ATTR)
Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis
Journal of Clinical Medicine
Transthyretin Amyloidosis (ATTR)
Impact of Patisiran on Polyneuropathy of Hereditary Transthyretin Amyloidosis in Patients with a V122I or T60A Variant: A Phase IV Multicentre Study
Annals of Medicine
Transthyretin Amyloidosis (ATTR)
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Effects of Vutrisiran on Cardiac Structure and Function in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Secondary Outcomes of the HELIOS-B Trial
Nature Medicine
Transthyretin Amyloidosis (ATTR)
Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B
JACC: Advances
Transthyretin Amyloidosis (ATTR)
Realising the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis
Molecular Therapy Nucleic Acids
Transthyretin Amyloidosis (ATTR)
Treatment with vutrisiran in individuals with transthyretin amyloidosis with cardiomyopathy: A plain language summary
Future Cardiology
Transthyretin Amyloidosis (ATTR)
Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B
Journal of the American College of Cardiology
Primary Hyperoxaluria Type 1 (PH1)
Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-Up of the Phase 3 Illuminate-C Trial
American Journal of Kidney Diseases
